MLPM2012
Machine Learning for Personalized Medicine
| Coordinatore | EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH
Organization address
address: Raemistrasse 101 contact info |
| Nazionalità Coordinatore | Switzerland [CH] |
| Sito del progetto | http://www.mlpm.eu |
| Totale costo | 3˙758˙056 € |
| EC contributo | 3˙758˙056 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-01-01 - 2016-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH
Organization address
address: Raemistrasse 101 contact info |
CH (ZUERICH) | coordinator | 595˙024.06 |
| 2 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 646˙888.70 |
| 3 |
ASSOCIATION POUR LA RECHERCHE ET LE DEVELOPPEMENT DES METHODES ET PROCESSUS INDUSTRIELS - ARMINES
Organization address
address: Boulevard Saint-Michel 60 contact info |
FR (PARIS) | participant | 520˙165.03 |
| 4 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | participant | 293˙324.38 |
| 5 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 264˙216.38 |
| 6 |
PHARMATICS LIMITED
Organization address
address: "9 Little France Road, Edinburgh BioQuarter" contact info |
UK (EDINBURGH) | participant | 258˙919.88 |
| 7 |
Sloan-Kettering Institute for Cancer Research CORPORATION
Organization address
address: York Avenue 1275 contact info |
US (New York) | participant | 240˙675.50 |
| 8 |
UNIVERSITE DE LIEGE
Organization address
city: LIEGE contact info |
BE (LIEGE) | participant | 238˙607.73 |
| 9 |
FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPE FELIPE
Organization address
address: CALLE EDUARDO PRIMO YUFERA 3 contact info |
ES (VALENCIA) | participant | 234˙949.34 |
| 10 |
UNIVERSIDAD CARLOS III DE MADRID
Organization address
address: CALLE MADRID 126 contact info |
ES (GETAFE (MADRID)) | participant | 234˙949.34 |
| 11 |
SIEMENS AKTIENGESELLSCHAFT
Organization address
address: Wittelsbacherplatz 2 contact info |
DE (MUNCHEN) | participant | 230˙336.60 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Over the last decade, enormous progress has been made on recording the health state of an individual patient down to the molecular level of gene activity and genomic information – even sequencing a patient’s genome for less than 1000 dollars is no longer an unrealistic goal. However, the ultimate hope to use all this information for personalized medicine, that is to tailor medical treatment to the needs of an individual, remains largely unfulfilled. To turn the vision of personalized medicine into reality, many methodological problems remain to be solved: there is a lack of methods that allow us to gain a causal understanding of the underlying disease mechanisms, including gene-gene and gene-environment interactions. Similarly, there is an urgent need for integration of the heterogeneous patient data currently available, for improved and robust biomarker discovery for disease diagnosis, prognosis and therapy outcome prediction. The field of machine learning, which tries to detect patterns, rules and statistical dependencies in large datasets, has also witnessed dramatic progress over the last decade and has had a profound impact on the Internet. Amongst others, advanced methods for high-dimensional feature selection, causality inference, and data integration have been developed or are topics of current research. These techniques address many of the key methodological challenges that personalized medicine faces today and keep it from rising to the next level.
Despite this rich potential of machine learning in personalized medicine, its impact on data-driven medicine remains low, due to a lack of experts with knowledge in both machine learning and in statistical genetics. Our ITN aims to close this gap by bringing together leading European research institutes in Machine Learning and Statistical Genetics, both from the private and public sector, to train 14 early stage researchers.'